Revenue Analysis - BIIB
Comprehensive quarterly and annual revenue breakdown by product lines and geographic regions to identify growth drivers and market opportunities.
BIIB Corporation
Revenue by Product Line
Latest quarterly revenue breakdown by product segments
Quarterly Product Revenue
Product Revenue Details
Detailed breakdown of revenue by product line
MS Product Revenues
0.0% of total revenue
$1.1B
TYSABRI product
0.0% of total revenue
$454.6M
Fumarate
0.0% of total revenue
$405.9M
SPINRAZA
0.0% of total revenue
$392.7M
Interferon
0.0% of total revenue
$246.7M
Historical Revenue Data
Quarterly product revenue breakdown over time (Last 6 records)
| Date | Fumarate | Interferon | MS Product Revenues | SPINRAZA | TYSABRI product |
|---|---|---|---|---|---|
| 6/30/2025 | $405.9M | $246.7M | $1.1B | $392.7M | $454.6M |
| 3/31/2025 | $344.9M | $226.3M | $953.0M | $423.9M | $381.5M |
| 12/31/2024 | $404.4M | $236.0M | $1.1B | $421.4M | $415.4M |
| 9/30/2024 | $390.9M | $237.5M | $1.1B | $381.4M | $406.1M |
| 6/30/2024 | $418.0M | $250.9M | $1.1B | $429.1M | $462.2M |
| 3/31/2024 | $381.8M | $243.6M | $1.1B | $341.3M | $431.3M |
Revenue Trend Analysis
Analysis of major growing and declining segments based on recent revenue data
Product Segments
Growing Segments
TYSABRI product+19.2%
Fumarate+17.7%
MS Product Revenues+16.2%